The Institute for Clinical and Industrial Research 's ( CSI ) analysis of experimental gene therapy Zolgensma from Novartis found it would be more cost effective than Biogen 's Spinzara therapy if priced at $ 2 m . Dave Lennon , president of Novartis ' AveXis unit , said CSI 's report is positive for cell - based therapies and gene - therapy assessments but highlighted the need for bio - pharmaceutical companies to consider developing alternative payment models for such treatments . Novartis already offers an outcome - based payment model for its blood cancer treatment Kymriah and ultimately , Lennon said , the onus will be on treatment developers to prove the value of their therapies .
The Institute for Clinical and Economic Review's (ICER) analysis of experimental gene therapy Zolgensma from Novartis found it would be more cost effective than Biogen's Spinzara therapy if priced at $2m. Dave Lennon, president of Novartis' AveXis unit, said ICER's report is positive for cell-based therapies and gene-therapy assessments but highlights the need for bio-pharmaceutical companies to consider offering alternative payment models for such therapies. Novartis already offers an outcome-based payment model for its blood cancer treatment Kymriah and ultimately, Lennon said, the onus will be on treatment developers to prove the value of their therapies.